Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402087 | 0.87 | KMT2A (0.52) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL6762639 | 0.87 | KMT2A (0.52) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL15960134 | 0.87 | KMT2A (0.52) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL6801346 | 0.86 | CASP3 (0.46) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL8653524 | 0.86 | CASP3 (0.52) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL377861 | 0.86 | CASP3 (0.52) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL2133922 | 0.86 | CASP3 (0.52) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL20371129 | 0.83 | KMT2A (0.51) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL13946516 | 0.83 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL1253102 | 0.83 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | MDM4 4254/4885TP53 819/4885CASP3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.